Supornpun Napamon, Rummaneethorn Paisal, Nararatwanchai Thamthiwat, Saiwichai Tawee, Chaichalotornkul Sirinthip
School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok, Thailand.
Faculty of Public Health, Mahidol University, Bangkok, Thailand.
J Cutan Aesthet Surg. 2022 Apr-Jun;15(2):168-174. doi: 10.4103/JCAS.JCAS_68_21.
Based on various Botulinum toxin A products, reports of the lower efficacy of Incobotulinum toxin A compared with Onabotulinum toxin A for muscle contouring were observed. In addition, complications of trapezius myalgia and shoulder contouring treatment from malpractice have been reported.
The study aimed at comparing the efficacy between Incobotulinum toxin A and Onabotulinum toxin A; research was conducted on a safe treatment technique for trapezius hypertrophy and trapezius myalgia.
A split-shoulder, double-blind, randomized controlled trial was performed. Twenty volunteers with trapezius hypertrophy and trapezius myalgia were randomly injected with 30 units of Incobotulinum toxin A and Onabotulinum toxin A in each trapezius muscle guided by ultrasound.
The trapezius thickness among those receiving treatment with Onabotulinum toxin A and Incobotulinum toxin A on day 60 was 7.35 ± 1.11 and 7.33 ± 1.21 mm, respectively, which did not portray a significant difference ( = 0.991). Compared with the muscle size from day 60 to one year, the size of the trapezius muscle that had been treated by Onabotulinum toxin type A regained a significantly larger size compared with that treated by Incobotulinum toxin A ( = 0.027). On comparing the size of the trapezius muscle treated by Incobotulinum toxin A between one year and day 0, it was observed that the trapezius thickness at one year had significantly decreased ( < 0.001). On comparing the pain score from day 60 to day 0, it was observed that the pain scores of trapezius myalgia treated by Onabotulinum toxin A and Incobotulinum toxin A significantly differed ( = 0.003).
Incobotulinum toxin A had the same efficacy but a longer lasting effect for the trapezius size contouring and a higher efficacy for trapezius myalgia treatment compared with Onabotulinum toxin A.
基于各种A型肉毒杆菌毒素产品，观察到与A型肉毒杆菌毒素相比，因卡肉毒杆菌毒素A在肌肉塑形方面疗效较低的报告。此外，还报告了因医疗事故导致的斜方肌疼痛和肩部塑形治疗并发症。
本研究旨在比较因卡肉毒杆菌毒素A和A型肉毒杆菌毒素之间的疗效；对斜方肌肥大和斜方肌疼痛的安全治疗技术进行研究。
进行了一项分肩、双盲、随机对照试验。20名患有斜方肌肥大和斜方肌疼痛的志愿者在超声引导下，每侧斜方肌随机注射30单位因卡肉毒杆菌毒素A和A型肉毒杆菌毒素。
在第60天时，接受A型肉毒杆菌毒素和因卡肉毒杆菌毒素A治疗的患者斜方肌厚度分别为7.35±1.11和7.33±1.21毫米，差异无统计学意义（P=0.991）。与第60天至1年时的肌肉大小相比，接受A型肉毒杆菌毒素治疗的斜方肌大小恢复得明显大于接受因卡肉毒杆菌毒素A治疗的斜方肌（P=0.027）。比较因卡肉毒杆菌毒素A治疗的斜方肌在1年和第0天时的大小，发现1年时斜方肌厚度显著降低（P<0.001）。比较第60天至第0天的疼痛评分，发现接受A型肉毒杆菌毒素和因卡肉毒杆菌毒素A治疗的斜方肌疼痛评分有显著差异（P=0.003）。
与A型肉毒杆菌毒素相比，因卡肉毒杆菌毒素A在斜方肌大小塑形方面疗效相同，但效果持续时间更长，在治疗斜方肌疼痛方面疗效更高。
